Tau oligomers in cerebrospinal fluid in Alzheimer's disease
Open accessAbstract
Objective: With an increasing incidence of Alzheimer's disease (AD) and neurodegenerative tauopathies, there is an urgent need to develop reliable biomarkers for the diagnosis and monitoring of the disease, such as the recently discovered toxic tau oligomers. Here, we aimed to demonstrate the presence of tau oligomers in the cerebrospinal fluid (CSF) of patients with cognitive deficits, and to determine whether tau oligomers could serve as a potential biomarker for AD. Methods: A multicentric collaborative study involving a double‐blinded analysis with a total of 98 subjects with moderate to severe AD (N = 41), mild AD (N = 31), and nondemented control subjects (N = 26), and two pilot studies of 33 total patients with AD (N = 19) and control (N = 14) subjects were performed. We carried out biochemical assays to measure oligomeric tau from CSF of these patients with various degrees of cognitive impairment as well as cognitively normal controls. Results: Using a highly reproducible indirect ELISA method, we found elevated levels of tau oligomers in AD patients compared to age‐matched controls. Western blot analysis confirmed the presence of oligomeric forms of tau in CSF. In addition, the ratio of oligomeric to total tau increased in the order: moderate to severe AD, mild AD, and controls. Conclusion: These assays are suitable for the analysis of human CSF samples. These results here suggest that CSF tau oligomer measurements could be optimized and added to the panel of CSF biomarkers for the accurate and early detection of AD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Tau oligomers and monomers are elevated in the cerebrospinal fluid of Alzheimer's disease patients.
“tau oligomers and monomers have been found elevated in the CSF of AD patients34,35”
From Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs) (2018) · cites this paper as [34]
Elevation of SASP components in AD patients correlates with CSF tau levels, inflammation, and cognitive impairment.
“This elevation of SASP components in AD patients correlates with CSF tau levels, inflammation, and cognitive impairment.”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Diagnostic and Statistical Manual of Mental Disorders
&NA; (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802020-00022 · Cited by 12,603 · see citing works
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · see citing works
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · see citing works
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · see citing works
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134 · see citing works
Self-citationAlbert, M., DeKosky, S. T., Dickson, D. W., Dubois, B., Feldman, H., Fox, N. C., Gamst, A. C., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.1.96 · Cited by 2,630 · see citing works
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works
Self-citationOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · see citing works
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works
Self-citation2015 Alzheimer's disease facts and figures
Alzheimer's Association (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,641 · see citing works
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233 · see citing works
The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
Sperling, R., Mormino, E., & Johnson, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.038 · Cited by 725 · see citing works
Mild Cognitive Impairment: An Overview
Petersen, R. C., & Negash, S. (2008) · CNS Spectrums · doi:10.1017/s1092852900016151 · Cited by 665 · see citing works
Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., et al. (2006) · Brain · doi:10.1093/brain/awl269 · Cited by 586 · see citing works
Identification of oligomers at early stages of tau aggregation in Alzheimer's disease
Lasagna‐Reeves, C. A., Castillo‐Carranza, D. L., Sengupta, U., Sarmiento, J., Troncoso, J., Jackson, G. R., & Kayed, R. (2012) · The FASEB Journal · doi:10.1096/fj.11-199851 · Cited by 527 · see citing works
Self-citationThe Clinical Problem of Symptomatic Alzheimer Disease and Mild Cognitive ImpairmentPreprint
Tarawneh, R. M., & Holtzman, D. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006148 · Cited by 474 · see citing works
Preparation and Characterization of Neurotoxic Tau Oligomers
Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Muñoz, M. J., Jackson, G. R., & Kayed, R. (2010) · Biochemistry · doi:10.1021/bi1016233 · Cited by 359 · see citing works
Self-citationCastillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278 · see citing works
Self-citationTemplate-assisted filament growth by parallel stacking of tau
Margittai, M., & Langen, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401911101 · Cited by 276 · see citing works
CSF Total tau, Aβ42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease
Blennow, K., Vanmechelen, E., & Hampel, H. J. (2001) · Molecular Neurobiology · doi:10.1385/mn:24:1-3:087 · Cited by 263 · see citing works
Self-citationCognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia
Rajan, K. B., Wilson, R. S., Weuve, J., Barnes, L. L., & Evans, D. A. (2015) · Neurology · doi:10.1212/wnl.0000000000001774 · Cited by 260 · see citing works
Tau immunotherapy for Alzheimer's disease
Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247 · see citing works
Cerebrospinal fluid tau and amyloid-β1-42in patients with dementia
Skillbäck, T. B., Farahmand, B. Y., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A. B., Winblad, B. G., Schott, J. M., et al. (2015) · Brain · doi:10.1093/brain/awv181 · Cited by 215 · see citing works
Self-citationFluid biomarkers in Alzheimer’s disease – current concepts
Rosén, C., Hansson, O., Blennow, K., & Zetterberg, H. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-20 · Cited by 214 · see citing works
Self-citationBiochemical markers in persons with preclinical familial Alzheimer disease
Ringman, J. M., Younkin, S. G., Pratico, D., Seltzer, W., Cole, G. M., Geschwind, D. H., Rodriguez-Agudelo, Y., Schaffer, B., Fein, J., Sokolow, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303973.71803.81 · Cited by 198 · see citing works
CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment
Herukka, S., Hallikainen, M., Soininen, H. S., & Pirttilä, T. (2005) · Neurology · doi:10.1212/01.wnl.0000156914.16988.56 · Cited by 189 · see citing works
Pathological Interface Between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies
Sengupta, U., Guerrero‐Munoz, M. J., Castillo‐Carranza, D. L., Lasagna‐Reeves, C. A., Gerson, J. E., Paulucci-Holthauzen, A. A., Krishnamurthy, S., Farhed, M., Jackson, G. R., & Kayed, R. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.12.019 · Cited by 181 · see citing works
Self-citationClinical Prediction of Alzheimer Disease Dementia Across the Spectrum of Mild Cognitive Impairment
Dickerson, B. C., Sperling, R. A., Hyman, B. T., Albert, M., & Blacker, D. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.12.1443 · Cited by 166 · see citing works
Cerebrospinal fluid markers for prediction of Alzheimer's disease
Zetterberg, H., Wahlund, L., & Blennow, K. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.08.011 · Cited by 162 · see citing works
Self-citationBlom, E. S., Giedraitis, V., Zetterberg, H., Fukumoto, H., Blennow, K., Hyman, B. T., Irizarry, M. C., Wahlund, L., Lannfelt, L., & Ingelsson, M. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000216841 · Cited by 141 · see citing works
Self-citationThe role of tau in the pathological process and clinical expression of Huntington’s disease
Vuono, R., Winder‐Rhodes, S., de Silva, R., Cisbani, G., Drouin‐Ouellet, J., REGISTRY Investigators of the European Huntington’s Disease Network, Spillantini, M. G., Cicchetti, F., & Barker, R. A. (2015) · Brain · doi:10.1093/brain/awv107 · Cited by 139 · see citing works
Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers
Parnetti, L., Lanari, A., Silvestrelli, G., Saggese, E., & Reboldi, G. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.09.022 · Cited by 101 · see citing works
Characterization of tau oligomeric seeds in progressive supranuclear palsy
Gerson, J. E., Sengupta, U., Lasagna‐Reeves, C. A., Guerrero‐Munoz, M. J., Troncoso, J. C., & Kayed, R. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-73 · Cited by 95 · see citing works
Self-citationAdvances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.
Sjögren, M., Andreasen, N., & Blennow, K. (2003) · Clinica chimica acta; international journal of clinical chemistry · doi:10.1016/s0009-8981(03)00121-9 · Cited by 88 · see citing works
Self-citationBlennow, K., & Zetterberg, H. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00345 · Cited by 77 · see citing works
Self-citationFrankfort, S. V., Tulner, L. R., van Campen, J., Verbeek, M. M., Jansen, R. W. M. M., & Beijnen, J. H. (2008) · Current Clinical Pharmacology · doi:10.2174/157488408784293723 · Cited by 77 · see citing works
Extensive p‐Tau Pathology and SDS‐Stable p‐Tau Oligomers in Alzheimer's Cortical Synapses
Henkins, K. M., Sokolow, S., Miller, C. A., Vinters, H. V., Poon, W. W., Cornwell, L. B., Saing, T., & Gylys, K. H. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00598.x · Cited by 70 · see citing works
Tau Oligomers as Potential Targets for Alzheimer’s Diagnosis and Novel Drugs
Guzmán‐Martínez, L., Farias, G. A., & Maccioni, R. B. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00167 · Cited by 62 · see citing works
Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer
Petra, E. S. (2012) · Frontiers in bioscience · doi:10.2741/4035 · Cited by 62 · see citing works
Rethinking on the concept of biomarkers in preclinical Alzheimer’s disease
Berti, V., Polito, C., Lombardi, G., Ferrari, C., Sorbi, S., & Pupi, A. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2477-1 · Cited by 51 · see citing works
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
Leko, M. B., Štrac, D. Š., Mück‐Šeler, D., Pivac, N., Stanić, G., Hof, P. R., & Šimić, G. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.347 · Cited by 46 · see citing works
Cerebrospinal fluid biomarkers for Alzheimerʼs disease
Zetterberg, H. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000179 · Cited by 42 · see citing works
Self-citationExpanding the Repertoire of Biomarkers for Alzheimer’s Disease: Targeted and Non-targeted Approaches
Galasko, D. R. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00256 · Cited by 18 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction
Nation, D. A., Sweeney, M. D., Montagne, A., Sagare, A. P., D’Orazio, L. M., Pachicano, M., Sepehrband, F., Nelson, A. R., Buennagel, D. P., Harrington, M. G., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0297-y · Cited by 1,728 · see citing works
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808 · see citing works
Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade
Gulisano, W., Maugeri, D., Baltrons, M. A., Fà, M., Amato, A., Palmeri, A., D’Adamio, L., Grassi, C., Devanand, D. P., Honig, L. S., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179935 · Cited by 313 · see citing works
Sengupta, U., & Kayed, R. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102270 · Cited by 303 · see citing works
Self-citationBatista, A. F., Forny‐Germano, L., Clarke, J. R., Silva, N. M. L. E., Brito‐Moreira, J., Boehnke, S. E., Winterborn, A., Coe, B. C., Lablans, A., Vital, J. F. S., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5056 · Cited by 246 · see citing works
Gaikwad, S., Puangmalai, N., Bittar, A., Montalbano, M., Garcia, S., McAllen, S., Bhatt, N., Sonawane, M., Sengupta, U., & Kayed, R. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109419 · Cited by 234 · see citing works
Self-citationRösler, T. W., Marvian, A. T., Brendel, M., Nykänen, N.-P., Höllerhage, M., Schwarz, S. C., Hopfner, F., Koeglsperger, T., Respondek, G., Schweyer, K., et al. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101644 · Cited by 219 · see citing works
Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs)
Rauch, J. N., Chen, J. J., Sorum, A. W., Miller, G. M., Sharf, T., See, S. K., Hsieh-Wilson, L. C., Kampmann, M., & Kosik, K. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-24904-z · Cited by 211 · see citing works
Updates in Alzheimer's disease: from basic research to diagnosis and therapies
Liu, E., Zhang, Y., & Wang, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 220 · see citing works
BIN1 favors the spreading of Tau via extracellular vesicles
Crotti, A., Sait, H. R., McAvoy, K. M., Estrada, K., Ergun, A., Szak, S., Marsh, G., Jandreski, L., Peterson, M., Reynolds, T. L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45676-0 · Cited by 171 · see citing works
LTP and memory impairment caused by extracellular Aβ and Tau oligomers is APP-dependent
Puzzo, D., Piacentini, R., Fá, M., Gulisano, W., Li Puma, D. D., Staniszewski, A., Zhang, H., Tropea, M. R., Cocco, S., Palmeri, A., et al. (2017) · eLife · doi:10.7554/elife.26991 · Cited by 172 · see citing works
Rinauro, D. J., Chiti, F., Vendruscolo, M., & Limbocker, R. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00651-2 · Cited by 132 · see citing works
Alzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129 · see citing works
Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases
Choi, M. L., & Gandhi, S. (2018) · FEBS Journal · doi:10.1111/febs.14587 · Cited by 128 · see citing works
Gaikwad, S., Senapati, S., Haque, M. A., & Kayed, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13490 · Cited by 117 · see citing works
Self-citationKulenkampff, K., Perez, A.-M. W., Sormanni, P., Habchi, J., & Vendruscolo, M. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00254-9 · Cited by 110 · see citing works
Gonçalves, R. A., Wijesekara, N., Fraser, P. E., & Felice, F. G. D. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00017 · Cited by 107 · see citing works
The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer′s Disease (AD)
Mroczko, B., Groblewska, M., & Litman‐Zawadzka, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194661 · Cited by 106 · see citing works
Advances and considerations in AD tau-targeted immunotherapy
Bittar, A., Bhatt, N. N., & Kayed, R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104707 · Cited by 105 · see citing works
Self-citationCurrent Status of Clinical Trials on Tau Immunotherapies
Ji, C., & Sigurdsson, E. M. (2021) · Drugs · doi:10.1007/s40265-021-01546-6 · Cited by 96 · see citing works
Tau immunotherapies: Lessons learned, current status and future considerations
Sandusky-Beltran, L. A., & Sigurdsson, E. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108104 · Cited by 90 · see citing works
Moore, K. B. E., Hung, T.-J., & Fortin, J. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103487 · Cited by 86 · see citing works
Puangmalai, N., Sengupta, U., Bhatt, N., Gaikwad, S., Montalbano, M., Bhuyan, A., Garcia, S., McAllen, S., Sonawane, M., Jerez, C., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101766 · Cited by 68 · see citing works
Self-citationLebouvier, T., Pasquier, F., & Buée, L. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000502 · Cited by 68 · see citing works
Extracellular tau induces microglial phagocytosis of living neurons in cell cultures
Pampuščenko, K., Morkūnienė, R., Šneideris, T., Smirnovas, V., Budvytytė, R., Valinčius, G., Brown, G. C., & Borutaitė, V. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14940 · Cited by 62 · see citing works
Modulating disease-relevant tau oligomeric strains by small molecules
Cascio, F. L., García, S., Montalbano, M., Puangmalai, N., McAllen, S., Pace, A., Piccionello, A. P., & Kayed, R. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014630 · Cited by 51 · see citing works
Self-citationAmyloid oligomers as on-pathway precursors or off-pathway competitors of fibrils
Muschol, M., & Hoyer, W. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1120416 · Cited by 55 · see citing works
The RAGE Axis: A Relevant Inflammatory Hub in Human Diseases
Armando Rojas, R., Lindner, C., Schneider, I., González, I., & Uribarri, J. (2024) · Biomolecules · doi:10.3390/biom14040412 · Cited by 61 · see citing works
Montalbano, M., McAllen, S., Sengupta, U., Puangmalai, N., Bhatt, N. N., Ellsworth, A., & Kayed, R. (2019) · Aging Cell · doi:10.1111/acel.13035 · Cited by 45 · see citing works
Self-citationThe prion-like transmission of tau oligomers via exosomes
Jackson, N. A., Guerrero‐Munoz, M. J., & Castillo‐Carranza, D. L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.974414 · Cited by 44 · see citing works
Self-citationBlömeke, L., Pils, M., Kraemer‐Schulien, V., Dybala, A., Schaffrath, A., Kulawik, A., Rehn, F., Cousin, A., Nischwitz, V., Willbold, J., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00330-x · Cited by 44 · see citing works
Distinct Conformations, Aggregation and Cellular Internalization of Different Tau Strains
Karikari, T. K., Nagel, D. A., Grainger, A. I., Clarke-Bland, C., Crowe, J. A., Hill, E. J., & Moffat, K. G. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00296 · Cited by 39 · see citing works
Knockin’ on heaven’s door: Molecular mechanisms of neuronal tau uptake
La‐Rocque, S. D., Moretto, E., Butnaru, I., & Schiavo, G. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15144 · Cited by 42 · see citing works
Martín-Cámara, O., Cores, Á., López‐Alvarado, P., & Menéndez, J. C. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113742 · Cited by 39 · see citing works
Tropea, M. R., Puma, D. D. L., Melone, M., Gulisano, W., Arancio, O., Grassi, C., Conti, F., & Puzzo, D. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102154 · Cited by 39 · see citing works
Li, X., Han, J., Bujaranipalli, S., He, J., Kim, E. Y., Kim, H. Y., Im, J. H., & Cho, W. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114444 · Cited by 37 · see citing works
Hu, J., Sha, W., Yuan, S., Wu, J., & Huang, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241915023 · Cited by 35 · see citing works
Tau Oligomers in Sera of Patients with Alzheimer’s Disease and Aged Controls
Kolarova, M., Sengupta, U., Bartos, A., Ricny, J., & Kayed, R. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170048 · Cited by 27 · see citing works
Self-citationSong, H.-L., Kim, N.-Y., Park, J., Kim, M. I., Jeon, Y.-N., Lee, S.-J., Cho, K., Shim, Y.-L., Lee, K.-H., Mun, Y.-S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci156537 · Cited by 26 · see citing works
Song, L., Oseid, D. E., Wells, E. A., Coaston, T. N., & Robinson, A. S. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01943-2 · Cited by 26 · see citing works
Structure-specific amyloid precipitation in biofluids
Rodrigues, M., Bhattacharjee, P., Brinkmalm, A., Do, D. T., Pearson, C. M., De, S., Ponjavic, A., Varela, J. A., Kulenkampff, K., Baudrexel, I., et al. (2022) · Nature Chemistry · doi:10.1038/s41557-022-00976-3 · Cited by 26 · see citing works
Self-citationHeme Oxygenase 1 Induces Tau Oligomer Formation and Synapse Aberrations in Hippocampal Neurons
Si, Z., Wang, X., Zhang, Z., Wang, J., Li, J., Li, J., Li, L., Li, Y., Peng, Y., Sun, C., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180451 · Cited by 23 · see citing works
Neurosteroids and Oxysterols as Potential Therapeutic Agents for Glaucoma and Alzheimer’s Disease
Ishikawa, M., Yoshitomi, T., Covey, D. F., Zorumski, C. F., & Izumi, Y. (2018) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000356 · Cited by 22 · see citing works
Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology
Blömeke, L., Rehn, F., Kraemer‐Schulien, V., Kutzsche, J., Pils, M., Bujnicki, T., Lewczuk, P., Kornhuber, J., Freiesleben, S. D., Schneider, L., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12589 · Cited by 22 · see citing works
Kotarba, S., Kozłowska, M., Scios, M., Saramowicz, K., Barczuk, J., Granek, Z., Siwecka, N., Wiese, W., Golberg, M., Galita, G., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910797 · Cited by 21 · see citing works
Arastoo, M., Lofthouse, R. A., Penny, L. K., Harrington, C. R., Porter, A., Wischik, C. M., & Palliyil, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228673 · Cited by 21 · see citing works
Raber, J., Perez, R., Torres, E. R. S., Krenik, D., Boutros, S. W., Patel, E. M., Chlebowski, A. C., Torres, E. R., Perveen, Z., Penn, A. L., et al. (2021) · Environmental Health Perspectives · doi:10.1289/ehp8428 · Cited by 19 · see citing works
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions
Loeffler, D. A. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00459 · Cited by 19 · see citing works
Tau protein aggregation associated with SARS-CoV-2 main protease
Eberle, R. J., Coronado, M. A., Gering, I., Sommerhage, S., Korostov, K., Stefanski, A., Stühler, K., Kraemer‐Schulien, V., Blömeke, L., Bannach, O., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288138 · Cited by 18 · see citing works
Hossen, F., Sun, G. Y., & Lee, J. C. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.05.044 · Cited by 18 · see citing works
Biosensing strategies for amyloid‐like protein aggregates
Zhou, Y., Yan, S., Dong, W., Wu, C., Zhao, Z., Wang, R., Duo, Y., Huang, Y., Xu, D., & Jiang, C. (2024) · BMEMat · doi:10.1002/bmm2.12053 · Cited by 16 · see citing works
Disease-modifying strategies in primary tauopathies
Rösler, T. W., Costa, M., & Höglinger, G. U. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107842 · Cited by 14 · see citing works
Yang, C., Li, X., Zhang, L., Li, Y., Li, L., & Zhang, L. (2019) · Journal of Natural Medicines · doi:10.1007/s11418-019-01318-3 · Cited by 13 · see citing works
Tau Diagnostics and Clinical Studies
Gozes, I., Höglinger, G. U., Quinn, J. P., Hooper, N. M., & Höglund, K. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0983-0 · Cited by 12 · see citing works
The Fate of Tau Aggregates Between Clearance and Transmission
Seitkazina, A., Kim, K. H., Fagan, E., Sung, Y., Kim, Y. K., & Lim, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.932541 · Cited by 10 · see citing works
Re-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach
Haut, F., Argyrousi, E. K., & Arancio, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010259 · Cited by 11 · see citing works
Fiorini, M., Bongianni, M., Benedetti, M. D., Monaco, S., & Zanusso, G. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180616 · Cited by 10 · see citing works
Arar, S. H., Haque, M. A., Bhatt, N. N., Zhao, Y., & Kayed, R. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00614 · Cited by 9 · see citing works
Self-citationMikuła, E., & Malecka, K. (2023) · Coatings · doi:10.3390/coatings13020235 · Cited by 7 · see citing works
Sengupta, U., & Kayed, R. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3629-9_9 · Cited by 7 · see citing works
Self-citationDivergent disruptive effects of soluble recombinant tau assemblies on synaptic plasticity in vivo
Yang, Y., Ondrejčák, T., Hu, N., Klyubin, I. V., & Rowan, M. J. (2025) · Molecular Brain · doi:10.1186/s13041-025-01208-8 · Cited by 5 · see citing works
Pareja-Navarro, K. A., King, C. D., Kauwe, G., Ngwala, Y. Y., Lokitiyakul, D., Wong, I., Vira, A., Liu, Y., Chen, J. H., Sharma, M., et al. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00928-2 · Cited by 5 · see citing works
Targeted tau protein degradation: a promising therapeutic approach for tauopathies
Baazaoui, N., Alfaifi, M. Y., Shati, A. A., Saad, R. B., & Garzoli, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.11.041 · Cited by 4 · see citing works
Tau protein aggregation associated with SARS-CoV-2 main proteasePreprint
Eberle, R. J., Coronado, M. A., Gering, I., Korostov, K., Stefanski, A., Stühler, K., Kraemer‐Schulien, V., Blömeke, L., Bannach, O., & Willbold, D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.04.531078 · Cited by 4 · see citing works
Central and peripheral tau retention modulated by an anti-tau antibodyPreprint
Solorzano, A. G., Brady, M., Bhatt, N. N., Johnson, A., Burgess, B., Leyva, H., Puangmalai, N., Jerez, C., Wood, R. W., Kayed, R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.17.553682 · Cited by 4 · see citing works
Self-citationHossen, F., Hung, J., Odeh, H., Sun, G. Y., & Lee, J. C. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1671986 · Cited by 2 · see citing works
Obulesu, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816412-9.00001-x · Cited by 2 · see citing works
Arar, S. H., Haque, M. A., Kayed, A., Khan, S., Bhatt, N. N., Zhao, Y., & Kayed, R. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00122 · Cited by 1 · see citing works
Self-citationInjury-induced tau pathology promotes aggressive behavior in Drosophila without neurodegeneration
Maxson, R., Smoyer, C. J., Hampton, M. F., Shen, Y., Wiese, K., Yee, C., Singh, A., Funtila, A., McKenney, R. J., & Ori-McKenney, K. M. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2600627123 · Cited by 1 · see citing works
Tropea, M. R., Puma, D. D. L., Melone, M., Gulisano, W., Arancio, O., Grassi, C., Conti, F., & Puzzo, D. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.05.425382
Song, L., Oseid, D. E., Wells, E. A., Coaston, T. N., & Robinson, A. S. (2021) · Research Square · doi:10.21203/rs.3.rs-647000/v1
Injury-induced tau pathology promotes aggressive behavior in Drosophila without neurodegenerationPreprint
Maxson, R., Smoyer, C. J., Hampton, M. F., Shen, Y., Wiese, K., Yee, C., Singh, A., Funtila, A., Mckenney, R. J., & Ori-McKenney, K. M. (2025) · bioRxiv · doi:10.1101/2025.11.22.689595
Garza, T. N., & Abisambra, J. F. (2026) · Cells · doi:10.3390/cells15151365
Berto, M., Urbina, P. A. M., Paradisi, A., Sensi, M., Iacovino, N., Carbone, C., Bedin, R., Pinti, M., Biscarini, F., Zamboni, G., et al. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.71634
Rethinking tau‐targeted therapy in Alzheimer's disease: Toward a dual biomarker strategy
Teunissen, C. E., Pini, L., & Imbimbo, B. P. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71867
- Authors
- Sengupta, U., Portelius, E., Hansson, O., Farmer, K., Castillo‐Carranza, D., Woltjer, R., Zetterberg, H., Galasko, D., Blennow, K., & Kayed, R.
- Affiliations
- The University of Texas Medical Branch at Galveston (US)
- University of Gothenburg (SE)
- Lund University (SE)
- Oregon Health & Science University (US)
- National Hospital for Neurology and Neurosurgery (GB)
- University of California San Diego (US)
- Corresponding author
- Kayed, Rakez
- ORCID
- Venue
- Annals of Clinical and Translational Neurology
- Publisher
- Wiley
- Published
- 2017-03
- Volume
- 4
- Issue
- 4
- Pages
- 226-235
- ISSN
- 2328-9503 (ISSN-L)
- PMC
- PMC5376754
- OpenAlex
- W2594587078
- Cited by
- 77
- References
- 45
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 8 · 2023: 11 · 2022: 8 · 2021: 8 · 2020: 5 · 2019: 12 · 2018: 8 · 2017: 7
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Annals of Clinical and Translational Neurology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health (RO1AG054025)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
- Keywords
- tau oligomers, Alzheimer's disease, cerebrospinal fluid biomarkers, indirect ELISA, early detection of Alzheimer's disease, cognitive impairment, tauopathy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
